Myocardial infarct: Depiction with contrast-enhanced MR imaging - Comparison of gadopentetate and gadobenate

Radiology

Volumn 236, Issue 3, 2005, Pages 1041-1046

  Schlosser, Thomas ^a   Hunold, Peter ^a   Herborn, Christoph U ^a   Lehmkuhl, Heidrun ^a   Lind, Alexander ^a   Massing, Sandra ^a   Barkhausen, Jörg ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG EFFICACY; ENDOCARDIUM; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE QUALITY; MALE; MATHEMATICAL PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; MYOCARDIAL INFARCTION; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 23844485892     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2363040220     Document Type: Article

References (35)

1. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage: results of clinical trials and the animal paradigm-paradoxic or predictable? Circulation 1993;88:296-306.
2. Pagano D, Lewis ME, Townend JN, Davies P, Camici PG, Bonser RS. Coronary revascularisation for postischaemic heart failure: how myocardial viability affects survival. Heart 1999;82:684-688.
3. Miller TD, Christian TF, Hopfenspirger MR, Hodge DO, Gersh BJ, Gibbons RJ. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 1995;92:334-341.
4. Di Carli MF, Maddahi J, Rokhsar S, et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 1998;116:997-1004.
5. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997;30:1693-1700.
6. Pagley PR, Beller GA, Watson DD, Gimple LW, Ragosta M. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. Circulation 1997;96: 793-800.
7. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100: 1992-2002.
8. Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105:224-229.
9. Simonetti OP, Kim RJ, Fieno DS, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 2001;218:215-223.
10. Oshinski JN, Yang Z, Jones JR, Mata JF, French BA. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2001;104:2838-2842.
11. Sandstede JJ, Beer M, Lipke C, et al. Time course of contrast enhancement patterns after Gd-BOPTA in correlation to myocardial infarction and viability: a feasibility study. J Magn Reson Imaging 2001;14: 789-794.
12. Gerber BL, Garot J, Bluemke DA, Wu KC, Lima JA. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002;106:1083-1089.
13. van Dijkman PR, Hold KM, van der Laarse A, et al. Sequential analysis of infarcted and normal myocardium in piglets using in vivo gadolinium-enhanced MR images. Magn Reson Imaging 1993;11:207-218.
14. Messroghli DR, Niendorf T, Schulz-Menger J, Dietz R, Friedrich MG. T1 mapping in patients with acute myocardial infarction. J Cardiovasc Magn Reson 2003;5:353-359.
15. Decking UK, Pai VM, Wen H, Balaban RS. Does binding of Gd-DTPA to myocardial tissue contribute to late enhancement in a model of acute myocardial infarction? Magn Reson Med 2003;49:168-171.
16. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-796.
17. Wendland MF, Saeed M, Lauerma K, et al. Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus GD-DTPA on inversion recovery EPI. Magn Reson Med 1997;37:448-456.
18. Scheffler K, Hennig J. T(1) quantification with inversion recovery TrueFISP. Magn Reson Med 2001;45:720-723.
19. Applegate KE, Tello R, Ying J. Hypothesis testing KI: counts and medians. Radiology 2003;228:603-608.
20. Sonnad SS. Describing data: statistical and graphical methods. Radiology 2002;225: 622-628.
21. McNamara MT, Higgins CB, Ehman RL, Revel D, Sievers R, Brasch RC. Acute myocardial ischemia: magnetic resonance contrast enhancement with gadolinium-DTPA. Radiology 1984;153:157-163.
22. Wesbey GE, Higgins CB, McNamara MT, et al. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology 1984;153: 165-169.
23. Hunold P, Brandt-Mainz K, Freudenberg L, et al. Evaluation of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison of the late enhancement technique with positronemission tomography [in German]. Rofo 2002; 174:867-873.
24. Cavagna FM, Dapra M, Castelli PM, Maggioni F, Kirchin MA. Trends and developments in MRI contrast agent research. Eur Radiol 1997;7(suppl 5):222-224.
25. Earls JP, Bluemke DA. New MR imaging contrast agents. Magn Reson Imaging Clin N Am 1999;7:255-273.
26. Daldrup-Link HE, Brasch RC. Macromolecular contrast agents for MR mammography: current status. Eur Radiol 2003;13: 354-365.
27. Goyen M, Ruehm SG, Debatin JF. MR-angiography: the role of contrast agents. Eur J Radiol 2000;34:247-256.
28. Vittadini G, Felder E, Tirone P, Lorusso V. B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 1988;23(suppl 1):S246-S248.
29. Goyen M, Herborn CU, Lauenstein TC, et al. Optimization of contrast dosage for gadobenate dimeglumine-enhanced high-resolution whole-body 3D magnetic resonance angiography. Invest Radiol 2002;37: 263-268.
30. Herborn CU, Lauenstein TC, Ruehm SG, Bosk S, Debatin JF, Goyen M. Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography. Invest Radiol 2003;38:27-33.
31. Ruehm SG, Goyen M, Barkhausen J, et al. Rapid magnetic resonance angiography for detection of atherosclerosis. Lancet 2001;357:1086-1091.
32. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 2002;106:2322-2327.
33. Judd RM, Kim RJ. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2002;106:6.
34. Herborn CU, Barkhausen J, Paetsch I, et al. Coronary arteries: contrast-enhanced MR imaging with SH L 643A-experience in 12 volunteers. Radiology 2003;229:217-223.
35. Stuber M, Botnar RM, Danias PG, et al. Contrast agent-enhanced, free-breathing, three-dimensional coronary magnetic resonance angiography. J Magn Reson Imaging 1999;10:790-799.